hotspot -WSS

hotspot

author：comprehensive 2025-09-28 01:35:29 - browse：74

A sign of The Cigna Group in front of trees with orange and green leaves — insurance overage from STAT — Joe Buglewicz/Bloomberg

Cigna and Humana are in discussions to merge, a potential move that would create a health insurance and prescription drug benefits titan with approximately $300 billion of annual revenue.

A proposed transaction would almost certainly prompt a close review from antitrust enforcers at the Department of Justice and the Federal Trade Commission. A merged Cigna-Humana would further consolidate the market for pharmacy benefit managers. PBMs are companies that serve as the controversial middlemen of drug pricing negotiations, and of the four largest, two are owned by Cigna and Humana.

The Wall Street Journal first reported the talks between Cigna and Humana on Wednesday, citing sources close to the situation. Wendell Potter, a health insurance whistleblower who used to work at Cigna, also wrote about merger discussions between Cigna and Humana on his blog Tuesday.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： Fatty liver disease was alleviated by Lilly’s ‘triple

WSS

Being 'nonadherent' patient made me a more empathetic doctor

Archived: an online chat discussing Ebola, vaccines, and a new epidemic

Organ aging and disease risk measured by new blood test

Drug cartel violence flares in western Mexico after vigilante leader's killing

What don’t we know about an Alzheimer’s drug side effect?

UnitedHealth’s Optum accused of antitrust violations in California

knowledge

hotspot

hotspot

Bright Health sells Medicare Advantage business to Molina

UnitedHealth has 90,000 doctors — 10% of all physicians in U.S.

What does generative AI mean for health care? We asked experts

AstraZeneca lung cancer study comes in below expectations

What does generative AI mean for health care? We asked experts

Readout Newsletter: The latest in Pfizer, Moderna, and Sanofi

Peter Hotez and the public health issue of online harassment

What to do when lifesaving products contribute to climate change

Continuity nursing helped my family in our darkest PICU moments

CDC director unscathed in first congressional testimony

knowledge

Dexcom's push to bring CGM to type 2 diabetes patients

Takeda, Janssen join wearable maker to measure scratching

Penis shrinkage, a side effect of prostate cancer surgery, is temporary

U.K. Biobank has 500,000 peoples' genome sequences available

Trump’s hydroxychloroquine hype: a risk to my treatment and to him

BIO selects John Crowley as new CEO

hotspot

Wikipedia

explore

hotspot